SAMR approval priced in at that time with A2. vs discounted (no SAMR priced in) for BAL this time? maybe?
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025